Is Panacea Biotec Ltd (PANACEABIO) a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Panacea Biotec Ltd is a below average quality company .

Is Panacea Biotec Ltd (PANACEABIO) undervalued or overvalued?

The key valuation ratios of Panacea Biotec Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone .

What is Panacea Biotec Ltd (PANACEABIO) share price return in the past 10 years?

Panacea Biotec Ltd share price has appreciated 14.3% annually (CAGR) over the past ten years.

Is Panacea Biotec Ltd (PANACEABIO) a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Panacea Biotec Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing

What is the share price of Panacea Biotec Ltd (PANACEABIO)?

Company share prices are keep on changing according to the market conditions. The current trading price of Panacea Biotec Ltd (PANACEABIO) on 17-Apr-2026 16:59:59 at 16:59 is 358.00.

What is the market cap of Panacea Biotec Ltd (PANACEABIO)?

Market capitalization is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 17-Apr-2026 at 16:59, the market cap of Panacea Biotec stood at Rs. 2192.78 Cr.

What is the P/E ratio of Panacea Biotec?

The latest standalone P/E ratio of Panacea Biotec as of 17-Apr-2026 is 0.00.

What is the P/B ratio of Panacea Biotec Ltd (PANACEABIO)?

The latest standalone P/B ratio of Panacea Biotec Ltd (PANACEABIO) as of 17-Apr-2026 is 7.71.

What is the 52-week high and low of Panacea Biotec Ltd (PANACEABIO)?

The 52-week high of Panacea Biotec Ltd (PANACEABIO) is Rs. 581.00 and the 52-week low is Rs. 293.10.

What is the TTM revenue of Panacea Biotec Ltd (PANACEABIO)?

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Panacea Biotec is Rs. 370.27 (Cr.).

Panacea Biotec Ltd (PANACEABIO) Share Analysis – Quality, Pipeline & Valuation Zone & DeciZen Rating

Name: Panacea Biotec Ltd (PANACEABIO)
Brand: Panacea Biotec

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	10.2%	1.5%	3%	11.5%	1.1%	-0.7%	-16.1%	-11.4%	4.1%	-2.1%	-
Value Creation Index ⓘ	-0.3	-0.9	-0.8	-0.2	-0.9	-1.1	-2.2	-1.8	-0.7	-1.2	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	647	530	574	444	490	344	236	257	360	310	370
Sales YoY Gr.	-	-18.1%	8.3%	-22.7%	10.3%	-29.8%	-31.5%	9.2%	39.9%	-13.8%	-
Adj EPS ⓘ	-4.6	-6.6	-11.1	-32.1	-19.8	-2.7	-15.2	-14.9	0.3	-2.6	-6.9
YoY Gr.	-	NA	NA	NA	NA	NA	NA	NA	NA	-870.6%	-
BVPS (₹) ⓘ	18.5	74.4	63.4	68.3	140.5	83	67.8	53.2	53.7	51.3	46.4
Adj Net Profit ⓘ	-28.2	-40.6	-67.7	-196	-121	-16.6	-93.2	-91	2.1	-16	-42
Cash Flow from Ops. ⓘ	97.9	104	172	107	-82.9	38.3	-52.7	-10.7	33.1	3.9	-
Debt/CF from Ops. ⓘ	10.4	9.9	5.6	6.4	-0.8	1.7	-1.6	-9.5	3.8	58	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-7.9%	-8.8%	9.6%	-13.8%
Adj EPS ⓘ	NA	NA	NA	-870.6%
BVPSⓘ	12%	-18.3%	-8.9%	-4.6%
Share Price	14.3%	6.9%	43.5%	-31.5%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	-5.2	-8.2	-16	-48.7	-18.5	-2.4	-20.2	-24.6	0.6	-5	-14.1
Op. Profit Mgn % ⓘ	18.7	14.7	15.2	-29.5	8.2	0.2	-30.6	-24.2	3.9	-2.2	-9.9
Net Profit Mgn % ⓘ	-4.4	-7.7	-11.8	-44.2	-24.8	-4.8	-39.6	-35.4	0.6	-5.2	-11.4
Debt to Equity ⓘ	7.8	2.2	2.5	1.7	0.1	0.1	0.2	0.3	0.4	0.7	-
Working Cap Days ⓘ	311	391	359	666	651	576	582	549	393	397	171
Cash Conv. Cycle ⓘ	26	47	-8	1	-39	-20	72	35	-18	14	-33

Recent Performance Summary

Sales growth is good in last 4 quarters at 22.98%

Return on Equity is Poor

Sales growth has been subdued in last 3 years 9.58%

	Standalone	Consolidated
TTM EPS (₹)	-6.9	-1.3
TTM Sales (₹ Cr.)	370	606
BVPS (₹) ⓘ	46.4	135.6
Reserves (₹ Cr.) ⓘ	278	824
P/BV ⓘ	7.71	2.64
PE ⓘ	0.00	0.00

From the Market
52 Week Low / High (₹)	293.10 / 581.00
All Time Low / High (₹)	3.35 / 581.00
Market Cap (₹ Cr.)	2,193
Equity (₹ Cr.)	6.1
Face Value (₹)	1
Industry PE ⓘ	42.1

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	647	530	574	444	490	344	236	257	360	310
Operating Expenses ⓘ +	534	461	493	591	480	343	308	320	345	317
Manufacturing Costs	63	63	36	40	32	43	79	50	67	68
Material Costs	214	169	197	180	151	176	112	163	142	103
Employee Cost	140	132	137	142	123	59	73	71	87	97
Other Costs ⓘ	117	97	123	229	174	64	44	36	50	49
Operating Profit ⓘ	113	69	81	-147	10	0	-73	-63	14	-7
Operating Profit Margin (%)	17.4%	13.1%	14.2%	-33.0%	2.1%	0.1%	-30.9%	-24.4%	3.9%	-2.2%
Other Income ⓘ +	26	54	18	8	44	21	13	34	25	17
Exceptional Items ⓘ	50	-38	0	334	-15	0	0	0	0	0
Interest ⓘ	115	104	103	105	147	8	7	10	14	15
Depreciation ⓘ	71	66	57	54	27	27	26	24	21	20
Profit Before Tax ⓘ	1	-84	-61	37	-136	-13	-94	-63	4	-26
Tax ⓘ	1	-11	11	11	17	2	0	25	1	-11
Profit After Tax	1	-73	-72	27	-153	-14	-94	-88	4	-15
PAT Margin (%)	0.1%	-13.7%	-12.5%	6.0%	-31.3%	-4.2%	-39.7%	-34.1%	1.0%	-4.9%
Adjusted EPS (₹)	0.1	-11.9	-11.7	4.3	-25.0	-2.4	-15.3	-14.3	0.6	-2.5
Dividend Payout Ratio (%)	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	540	456	388	418	861	508	415	326	329	314
Share Capital ⓘ	22	6	6	6	6	6	6	6	6	6
Reserves ⓘ	518	450	382	412	855	502	409	320	323	308
Debt +	997	934	765	158	64	62	84	102	125	228
Long Term Debt	779	714	571	88	60	62	84	102	125	161
Short Term Debt	218	220	194	69	4	0	0	0	0	68
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	174	227	242	78	136	124	145	129	116	165
Others Liabilities ⓘ	267	304	427	939	247	267	289	338	355	174
Total Liabilities ⓘ	1,978	1,920	1,822	1,593	1,307	962	933	895	925	881
Fixed Assets
Net Fixed Assets ⓘ +	988	942	891	496	447	398	416	385	357	348
Gross Block	1,518	1,537	1,543	1,088	864	826	865	852	827	837
Accumulated Depreciation	531	595	652	591	416	428	449	467	470	489
CWIP ⓘ	19	28	37	3	4	13	1	28	97	119
Investments ⓘ	395	345	345	3	3	0	0	0	0	0
Inventories	137	141	149	43	99	87	129	116	108	152
Trade Receivables	142	176	142	25	18	35	23	12	11	21
Cash Equivalents	9	7	12	8	61	89	43	43	12	62
Others Assets ⓘ	288	282	246	1,015	676	339	321	310	340	178
Total Assets ⓘ	1,978	1,920	1,822	1,593	1,307	962	933	895	925	881

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	98	104	172	107	-83	38	-53	-11	33	4
PBT ⓘ	1	-84	-61	37	-136	-13	-94	-63	4	-26
Adjustment ⓘ	133	184	160	-68	205	32	36	10	27	30
Changes in Working Capital ⓘ	-58	-3	73	137	-144	20	6	43	4	1
Tax Paid ⓘ	21	6	-0	0	-8	-1	-1	-1	-2	-1
Cash Flow From Investing Activity ⓘ +	23	-18	-3	-8	-19	-37	40	2	-47	-61
Capex	-2	-24	-15	-5	14	-11	-6	1	-69	-53
Net Investments	24	-1	-1	-4	-37	-30	44	-1	14	-15
Others ⓘ	1	7	13	1	5	3	2	2	8	7
Cash Flow From Financing Activity ⓘ +	-129	-91	-164	-98	109	-7	10	9	13	90
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	-39	-16	-29	-16	182	1	18	17	21	25
Interest Paid ⓘ	-61	-94	-109	-64	-39	-4	-9	-8	-9	-3
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-29	19	-26	-19	-34	-4	0	0	0	68
Net Cash Flow ⓘ	-8	-5	6	0	8	-6	-3	1	-1	33

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	0.77	-25.52	-17.03	6.59	-23.93	-2.11	-20.27	-23.64	1.08	-4.74
ROCE (%)	10.15	1.48	2.96	11.51	1.09	-0.7	-16.14	-11.36	4.08	-2.13
Asset Turnover Ratio	0.32	0.28	0.31	0.26	0.35	0.31	0.25	0.28	0.4	0.34
PAT to CFO Conversion(x)	98	N/A	N/A	3.96	N/A	N/A	N/A	N/A	8.25	N/A
Working Capital Days
Receivable Days	68	107	101	69	15	28	45	25	12	19
Inventory Days	78	93	92	79	51	98	167	173	113	152
Payable Days	307	433	434	325	259	269	438	307	316	499

About Panacea Biotec Ltd

The company has product portfolio thatâ€™s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.

Panacea Biotec is the third largest biotechnology company (as per ABLE Survey, 2006), as well as among the top 50 pharmaceutical companies (as per ORG IMS July 2006) of India.

The company has been granted patents across countries like USA, U.K., France, Germany, Italy, Sweden, Denmark, Spain, Finland, Switzerland, The Netherlands, New Zealand, Mexico, Brazil, Nigeria, Zimbabwe, Australia, South Africa, Japan, Russia, Canada, Ukraine, Korea and China are among others.

Collaboration/ Strategic alliances The company has collaborated with Cambridge Biostability, U.K to develop thermo stable vaccines.

It has collaborated with National Institute of Immunology, India for Japanese Encephalitis candidate vaccine.

PBL has entered in strategic alliance with Biotech Consortium India to develop, manufacture and market of Anthrax vaccine.

The company has entered into an in-licensing arrangement with National Institute of Health, USA for use of a peptide based product for generation of hair follicles and hair growth.

The company has collaborated with Netherlands Vaccine Institute for inactivated polio vaccine.

It has collaborated with NRDC- India for Foot & Mouth Disease vaccine for veterinary use and Bio Farma-Indonesia for Measles vaccine.

The exclusive products based on patented Drug Delivery System include Panimun Bioral (Cyclosporine), Willgo, ThankGod (for comprehensive management of haemorrohoids), Xeed (anti-tubercular FDC with innovative Drug Delivery for optimum bioavailability of Rifampicin), Nimulid Safeinject, Nimulid MD, Nimulid Transgel.

Commencing fiscal 2008, the company plans for international marketing of novel NDDS based pharmaceutical formulation products to the international markets, like USA, U.K., Germany, France, Latin American countries and Italy through marketing collaborations and are on the look out for partners for distribution & marketing.

Business areas Research and Development (R&D) â€“ Under this the company primarily focuses on New Chemical Entities (NCE), New Biological Entities (NBE) and Novel Drug Delivery System (NDDS). The company has a team of 200 scientists working on different aspect of research across its four R&D centers.

Vaccines- Under this the company has product portfolio of oral polio vaccines and Hepatitis-B vaccines. It is obtaining pre-qualifications for others vaccines. The company markets its vaccines through Chiron Panacea Vaccines, this is a 50:50 joint venture with Novartis Vaccines, U.K

Formulations- It has created flagship brands like Willgo for pain management, Glizid & Glizid-M for diabetes; Panimun Bioral and Mycept for kidney transplant.

Panacea Biotec in 2009 signed an agreement with Popular Pharma for technology transfer, marketing and distribution of vaccines. Popular Pharma is engaged in manufacturing life saving drugs and has presence in various countries.

In 2010 Panacea Biotech's Baddi unit gets US FDA approval
In 2011 PanaceBiotec - Panacea Biotec Launches - PacliALL
In 2012 Panacea Biotech launches Inactivated Polio Virus vaccine in Nigeria
PanaceBiotec - Panacea Biotec inaugurates state of the art Oncology Production Unit
PanaceBiotec - Panacea Biotec Entered into Strategic Alliance with Osmotica Pharmaceutical
Panacea Biotec wins order worth Rs 187 cr from Govt to supply polio vaccines.

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Panacea Biotec Ltd (PANACEABIO) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Panacea Biotec Share Price